Syros Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2012-01-01
- Employees
- 68
- Market Cap
- $42M
- Website
- http://www.syros.com
- Introduction
Syros Pharmaceuticals, Inc. engages in the development of gene control therapies for cancer and diseases. Its product candidates include SY-1425, SY-2101, and SY-5609. The company was founded by Richard A. Young, Nathanael S. Gray, and James E. Bradner on November 9, 2011 and is headquartered in Cambridge, MA.
A Study for Oral SY-2101 for Participants With Acute Promyelocytic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2021-08-09
- Last Posted Date
- 2024-01-23
- Lead Sponsor
- Syros Pharmaceuticals
- Target Recruit Count
- 16
- Registration Number
- NCT04996030
- Locations
- 🇺🇸
Weill Cornell Medical College, New York, New York, United States
🇺🇸University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Northwestern Memorial Hospital, Chicago, Illinois, United States
Tamibarotene Plus Venetoclax/Azacitidine in Participants with Newly Diagnosed AML
- Conditions
- Interventions
- First Posted Date
- 2021-05-27
- Last Posted Date
- 2024-10-14
- Lead Sponsor
- Syros Pharmaceuticals
- Target Recruit Count
- 95
- Registration Number
- NCT04905407
- Locations
- 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
🇫🇷Hôpital l'Archet- CHU de Nice, Nice, France
🇺🇸City of Hope, Duarte, California, United States
Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome
- Conditions
- Interventions
- First Posted Date
- 2021-03-15
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Syros Pharmaceuticals
- Target Recruit Count
- 550
- Registration Number
- NCT04797780
- Locations
- 🇺🇸
University of Arizona, Tucson, Arizona, United States
🇺🇸UC Irvine, Irvine, California, United States
🇺🇸University of Southern California, Los Angeles, California, United States
A Study of SY 5609, a Selective CDK7 Inhibitor, in Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2020-01-29
- Last Posted Date
- 2023-10-27
- Lead Sponsor
- Syros Pharmaceuticals
- Target Recruit Count
- 105
- Registration Number
- NCT04247126
- Locations
- 🇺🇸
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Sidney Kimmel Cancer Center, Philadelphia, Pennsylvania, United States
A Study of SY-1365 in Adult Patients With Advanced Solid Tumors
- First Posted Date
- 2017-05-01
- Last Posted Date
- 2021-03-09
- Lead Sponsor
- Syros Pharmaceuticals
- Target Recruit Count
- 107
- Registration Number
- NCT03134638
- Locations
- 🇺🇸
Palo Alto Medical Foundation Group, San Francisco, California, United States
🇺🇸Honor Health Research Institute, Scottsdale, Arizona, United States
🇺🇸University of Alabama at Birmingham, Birmingham, Alabama, United States
A Biomarker-Directed Phase 2 Trial of Tamibarotene (SY-1425) in Participants With Acute Myeloid Leukemia or Myelodysplastic Syndrome
- Conditions
- Interventions
- First Posted Date
- 2016-06-21
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Syros Pharmaceuticals
- Target Recruit Count
- 155
- Registration Number
- NCT02807558
- Locations
- 🇫🇷
CHU Amiens, Amiens, France
🇫🇷Centre Hospitalier de la Côte basque, Bayonne, France
🇫🇷Centre Hospitalier Universitiaire Hopital Avicenne, Bobigny, France